Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medipal Holdings ( (JP:7459) ) has issued an update.
Medipal Holdings reported consolidated net sales of ¥2.91 trillion for the nine months to December 31, 2025, up 3.7% year on year, while operating profit slipped 4.8% to ¥43.2 billion but ordinary profit rose 8.1% and profit attributable to owners of parent edged up 3.2%. Total assets expanded to ¥2.02 trillion and net assets to ¥783.9 billion, with the company maintaining its dividend policy and completing a share buyback and cancellation that lifted earnings per share, even as it forecasts modest full-year sales growth and a decline in operating profit and bottom-line earnings.
The most recent analyst rating on (JP:7459) stock is a Hold with a Yen3111.00 price target. To see the full list of analyst forecasts on Medipal Holdings stock, see the JP:7459 Stock Forecast page.
More about Medipal Holdings
Medipal Holdings is a Japan-based distributor focused on pharmaceuticals, medical devices and related healthcare products, operating primarily through wholesale channels. Listed on the Tokyo Stock Exchange under code 7459, it serves the domestic healthcare market with a broad product lineup and logistics capabilities aimed at hospitals, pharmacies and other medical institutions.
YTD Price Performance: 3.03%
Average Trading Volume: 339,421
Technical Sentiment Signal: Buy
Current Market Cap: Yen517.8B
Find detailed analytics on 7459 stock on TipRanks’ Stock Analysis page.